Biosite files amended PMA (pre-market approval) for CHF (congestive heart failure) test:
This article was originally published in Clinica
Executive Summary
Biosite Diagnostics has submitted to the US FDA an amendment to its PMA application for its Triage BNP test for congestive heart failure (CHF). The amendment contains data that was requested by an FDA advisory panel, which earlier this year turned down the company's original PMA. "We have submitted data using a control group whose ages closely match those of the population of CHF patients," said the San Diego, California, company. "We have provided more data relevant to female CHF patients and to patients in certain ethnic groups," it added. The test measures B-type natriuretic peptide in whole blood and plasma.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.